Organon & Co. (NYSE:OGN) Reports Quarterly Earnings Results

Organon & Co. (NYSE:OGN - Get Free Report) announced its quarterly earnings results on Thursday, revealing an earnings per share (EPS) of $0.83. This figure fell short of analysts' expectations, which had set the consensus estimate at $0.92, marking a miss of $0.09. The company's return on equity was notably high at 644.70%, while it reported a net margin of 20.30%. Additionally, Organon & Co. updated its guidance for the fiscal year 2025, providing an outlook for EPS.

Organon & Co. Stock Performance

On the day of the earnings announcement, Organon & Co.'s stock saw an increase of $1.43, reaching a trading price of $16.13. The trading volume was significantly higher than usual at 5,934,328 shares, as compared to its average volume of 2,687,397 shares. The company maintains a current ratio of 1.70, a quick ratio of 1.21, and a debt-to-equity ratio of 17.73. The stock's technical analysis indicates a 50-day moving average of $15.33 and a 200-day moving average of $17.54. Overall, Organon & Co. has a market capitalization of $4.15 billion, a price-to-earnings (P/E) ratio standing at 3.20, and a price-to-earnings growth (PEG) ratio of 0.83. The stock has ranged from a 52-week low of $13.87 to a 52-week high of $23.10.

Wall Street Analysts Forecast Growth

In a recent update, TD Cowen raised its rating on Organon & Co. to a "hold" on January 15. The ratings among analysts are varied; one has issued a sell rating, while two have given hold ratings, one analyst has rated it a buy, and another has issued a strong buy rating. According to MarketBeat, the average rating for the stock is currently rated as "Hold", with a consensus target price set at $21.33.

About Organon & Co.

Organon & Co. operates as a global pharmaceutical company, focusing on providing innovative health solutions through its range of prescription therapies. The company's key areas of expertise include women's health, biosimilars, and established brands. Founded on March 11, 2020, the company is based in Jersey City, New Jersey.

earnings, stock, performance